Luminex Corporation Fourth Quarter and Full Year 2009 Earnings Release Scheduled for February 4, 2010
15 January 2010 - 7:46AM
PR Newswire (US)
AUSTIN, Texas, Jan. 14 /PRNewswire-FirstCall/ -- Luminex
Corporation (NASDAQ:LMNX) today announced that it expects to report
fourth quarter and full year 2009 results on Thursday, February 4,
2010. Results are scheduled for release after the close of trading.
(Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)
Management will hold a conference call to discuss the operating
highlights and financial results for the fourth quarter and full
year ended December 31, 2009, on February 4, 2010, at 5:00 p.m.
Eastern time. The conference call will be webcast live and will be
accompanied by a slide presentation, both of which may be accessed
at Luminex Corporation's website at http://www.luminexcorp.com/.
Simply log on to the web at the address above, go to the Company
section and access the Investor Relations link. Please go to the
website at least 15 minutes prior to the call to register, download
and install any necessary audio/video software. If you are unable
to participate during the live webcast, the call and slides will be
archived for six months on the website using the 'replay' link. The
use of pop-up blocking software may impair your ability to view
webcasts. If you use this software, press and hold the CTRL key
when you click on the Register button. Please contact your IT group
if you are unable to override this feature. Unauthorized recording
or downloading of this event is not permitted. About Luminex
Corporation Luminex Corporation develops, manufactures and markets
proprietary biological testing technologies with applications
throughout the diagnostic and life sciences industries. The
Company's xMAP® multiplex solutions include an open-architecture,
multi-analyte technology platform that delivers fast, accurate and
cost-effective bioassay results to markets as diverse as
pharmaceutical drug discovery, clinical diagnostics and biomedical
research, including the genomics and proteomics research markets.
The Company's xMAP technology is sold worldwide and is already in
use in leading clinical laboratories as well as major
pharmaceutical, diagnostic and biotechnology companies. Further
information on Luminex Corporation or xMAP technology can be
obtained at http://www.luminexcorp.com/. Statements made in this
release that express Luminex's or management's intentions, plans,
beliefs, expectations or predictions of future events are
forward-looking statements. The words "believe," "expect,"
"intend," "estimate," "anticipate," "will," "could," "should" and
similar expressions are intended to further identify such
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. It is important to note that the
Company's actual results or performance could differ materially
from those anticipated or projected in such forwardlooking
statements. Factors that could cause Luminex's actual results or
performance to differ materially include risks and uncertainties
relating to, among others, market demand and acceptance of
Luminex's products, the Company's dependence on strategic partners
for development, commercialization and distribution of products,
concentration of the Company's revenue in a limited number of
strategic partners, fluctuations in quarterly results due to a
lengthy and unpredictable sales cycle and bulk purchases of
consumables, Luminex's ability to scale manufacturing operations
and manage operating expenses, gross margins and inventory levels,
potential shortages of components, competition, the timing of
regulatory approvals, the implementation, including any
modification, of the Company's strategic operating plans, risks and
uncertainties associated with implementing our acquisition strategy
and the ability to integrate acquired companies or selected assets
into our consolidated business operations, as well as the risks
discussed under the heading "Risk Factors" in Luminex's Reports on
Forms 10-K and 10-Q, as filed with the Securities and Exchange
Commission. The forward-looking statements contained herein
represent the judgment of Luminex as of the date of this press
release, and Luminex expressly disclaims any intent, obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect any change in Luminex's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
Luminex Corporate Contact: Harriss T. Currie Vice President,
Finance and Chief Financial Officer 512-219-8020 Luminex Investor
Relations Contact: Mimi Torrrington Director of Investor Relations
512-219-8020
http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO
DATASOURCE: Luminex Corporation CONTACT: Harriss T. Currie,
Corporate, Vice President, Finance and Chief Financial Officer,
+1-512-219-8020, , or Mimi Torrrington, Director of Investor
Relations, +1-512-219-8020, , both of Luminex Corporation Web Site:
http://www.luminexcorp.com/
Copyright
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024